Clinical Trial Update: A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether Enzalutamide increases seizure risk in metastatic castration-resistant prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 4 | Status: COMPLETED | Results posted: 2020-12-09